A phase I study of tremelimumab, durvalumab, and hypofractionated radiotherapy for metastatic gynecologic cancers

The efficacy of anti-PD-L1/PD-1 therapies has been demonstrated in women with metastatic cervical cancer. The impact and safety of dual checkpoint inhibitors combined with hypofractionated radiotherapy (RT) in women with metastatic gynecologic cancers remain an open question. We conducted a phase I study of durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) in conjunction with hypofractionated RT to confirm the safety and tolerability of this combination and early response rates in women with metastatic gynecologic malignancies.